News coverage

Stay up to date with the latest in Primary Biliary Cholangitis with downloadable summaries of key trials from the 2024 AASLD Liver Meeting.

Further findings on the efficacy and safety of ileal bile acid transporter inhibitors for patients with progressive familial intrahepatic cholestasis have been presented at the 2024 AASLD The Liver Meeting in San Diego, California, USA.

Dr Miki Scaravaglio talks through her proof-of-principle study findings for use of whole-exome sequencing to aid the diagnosis of people with adult-onset cholestatic liver disease.

Whole-exome sequencing led to definitive diagnoses for almost a quarter of patients with unexplained adult-onset cholestatic liver disease, say Italian researchers.

Dr Andrew Stolz reports on the relationship between alterations to the ABCB11 gene and the risk of drug-induced liver injury from anabolic steroids.

Professor Richard Thompson shares his PFIC poster findings on the long-term efficacy and safety data of the PEDFIC 2 trial and the relationship between serum bile acid and event-free survival in the MARCH and MARCH-ON trials.

Alterations to ABCB11 play a “pivotal role” in the development of drug-induced liver injury from anabolic steroids, US researchers reported at the 2024 AASLD The Liver Meeting in San Diego, California, USA.

Trial findings suggest that the IBAT inhibitor odevixibat does not prevent absorption of combined oral contraceptives in healthy women.

An EASL expert panel has developed clinical practice guidelines for the management of progressive familial intrahepatic cholestasis and other genetic cholestatic liver diseases.

Dr Adriaan Van der Meer shares his insights on the results from the combination trial of obeticholic acid and bezafibrate for PBC patients, presented at EASL 2024 in Milan, Italy. In addition, discover key findings and learn about the RECAPITULATE trial, focusing on real-world treatment outcomes.

Professor Mark Swain discusses the latest updates from the ASSURE trial of seladelpar, presented at EASL 2024, in Milan, Italy. Explore key findings on efficacy, safety, and interim long-term results of this study.

Professor Marco Carbone reviews the latest updates from the ELATIVE trial of elafibranor, presented at EASL 2024 in Milan, Italy. Discover key insights on efficacy, quality of life improvements, and the broader significance of these results.

ASSURE study findings show that seladelapr elicits a biochemical response in patients with primary biliary cholangitis and cirrhosis.

ELATIVE subanalysis confirms improved biochemical response with elafibranor over placebo for primary biliary cholangitis according to various different criteria.

Combining slow-release bezafibrate with obeticholic acid shows treatment potential for patients with primary biliary cholangitis.

ELATIVE trial results for pruritus show benefits for both severity and impact on the quality of life of patients with primary biliary cholangitis.

Prof. Andreas Kremer provides his insights on studies on second-line obeticholic acid presented at The Liver Meeting 2023: its use in a real-world setting and as combination therapy with bezafibrate.

Dr Kris Kowdley comments on some of the key data in primary biliary cholangitis, presented at The Liver Meeting 2023, including the ELATIVE trial involving elafibranor.

Dr Gideon Hirschfield discusses some of the highlights on primary biliary cholangitis from The Liver Meeting 2023, with a focus on the RESPONSE trial of seladelpar.

Obeticholic acid positively affects liver function among patients with primary biliary cholangitis in the second-line treatment setting.

ELATIVE trial shows that elafibranor significantly improves biochemical response in patients with primary biliary cholangitis with anti-pruritic benefits.

RESPONSE trial findings show seladelpar improves markers of disease activity and reduces pruritus in patients with primary biliary cholangitis.

Denosumab is comparable to bisphosphonates for treating osteoporosis in patients with primary biliary cholangitis, but with fewer adverse effects.

Combining obeticholic acid with bezafibrate 400 mg/day shows therapeutic potential in patients with primary biliary cholangitis in two phase 2 trials.